In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TriPath Imaging Finds a Friend

Executive Summary

TriPath Imaging is getting a financial boost from one of its founding technology and equity providers, Roche. The company--the merged result of three different cytology start-ups--needs the money to go up against the so-far only successful player in the automated cytology market, Cytyc, hoping to exploit a much broader platform of technologies.

You may also be interested in...



BD's Progress in Molecular Markers

Having already collaborated with Millennium Pharmaceuticals to find marker candidates for its molecular oncology program, BD is now tapping TriPath Imaging to help build an imaging system to analyze the markers. Its strategy of relying on partners means it has to give up some profits, but BD is confident that the results will yield a value high enough to make the program economically feasible. It's a model that other companies are likely to emulate as they move into molecular diagnostics.

Denmark Leads The Way On Speeding Up Approvals For Drug/IVD Combination Trials

While an EU-level project is underway to address delays to drug trials that are conducted in combination with IVD performance studies, Denmark has streamlined its processes to address the issue at the national level.

First-In-Class Vorasidenib Among Bumper Crop Of New EU Filings

Twelve new drugs are now being reviewed for potential EU marketing approval, including Servier’s vorasidenib for IDH-mutant diffuse glioma, which the company says could become the first targeted therapy for the malignant and incurable brain tumor.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel